Abstract 794P
Background
OCCC, compared to other histologies, are less responsive to platinum based chemotherapy and suffer a worse prognosis. ARID1A mutations (mt) are the most common mt in OCCC. ARID1A loss has been described to increase replication stress in various tumor models. Anti-metabolites like gem are effective in ARID1A-mt in-vitro.
Methods
We performed a retrospective analysis of the molecular features and treatment outcomes of advanced or relapsed OCCC pts treated at our institution between January 2000 to May 2022. Treatment response was assessed per RECIST1.1. Next-generation sequencing (NGS) was performed where sufficient archival tissue was available (n=60). We hypothesize that gem is more effective than non-gem therapies, especially in ARID1A-mt.
Results
Of 90 advanced or relapsed OCCC patients (pts), median age was 53 years, with median 1 prior line of treatment received. 67 (74.4%) received 2 or more lines, of whom 35 (52.2%) included gem based therapy, mostly in 2nd line (19/35). 12 pts received platinum-gem with bevacizumab (bev), 18 pts received platinum-gem, 5 received gem monotherapy. 30/60 (50%) were ARID1A-mt. Across all treatment lines, the disease control rate (DCR) to gem was 61.1%. In 2nd line, DCR was significantly better for gem over non gem (Odds Ratio (OR) OR 6.5, p=0.004), seemingly more for ARID1A-mt (OR of mt VS wild-type (wt) 28 VS 4.2). Early use of gem (2nd against later lines) and incorporation of bev significantly improved DCR on multivariate analysis (Early use OR 4.1, p: 0.04; Bev OR 7.2, p: 0.02). There was a trend to improved median progression-free survival (mPFS) of 2L gem against non-gem based therapy (7.2 versus 3.2 months(m); Hazard Ratio (HR): 3.48, p = 0.06). This was significant in ARID1A mts (gem VS non-gem: 295 VS 70 days; HR: 4.3, p=0.04) but not in ARID1A-wt (p=0.14). Overall survival was not statistically significant in this study.
Conclusions
This is the largest study of OCCC pts receiving gem based therapy. We show that gemcitabine improved DCR for all OCCC patients, and mPFS in ARID1A-mt especially when used earlier. To maximise gem efficacy, earlier treatment combined with bevacizumab should be considered in OCCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N.Y.L. Ngoi: Financial Interests, Institutional, Invited Speaker: MSD, AstraZeneca, ASGO, JSGO; Financial Interests, Institutional, Advisory Board: Merck/Pfizer, AstraZeneca. F. Blanc-Durand: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Member of Board of Directors: Cureety; Financial Interests, Institutional, Research Grant: AZ; Other, Travel: GSK. D.S. Tan: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Merck Serono, Roche, Eisai, GSK, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca, Bayer, MSD, Eisai, Roche, Genmab, GSK, Boehringer Ingelheim; Financial Interests, Personal, Stocks/Shares: Asian Microbiome Library (AMiLi); Financial Interests, Institutional, Research Grant: Roche, Bayer, Karyopharm Therapeutics, AstraZeneca; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Bergen Bio; Financial Interests, Institutional, Local PI: Zeria Pharmaceutical Co., Ltd., Bayer, Byondis B.V.; Non-Financial Interests, Leadership Role, Ex society president: Gynecologic Cancer Group Singapore; Non-Financial Interests, Member of Board of Directors: Gynaecologic Cancer Intergroup (GCIG); Non-Financial Interests, Leadership Role, Ex- Chair: Asia-Pacific Gynecologic Oncology Trials Group (APGOT); Non-Financial Interests, Institutional, Product Samples, Research Study: MSD, Eisai, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11